| Year |
Citation |
Score |
| 2023 |
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, et al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36892581 DOI: 10.1158/1078-0432.CCR-22-3168 |
0.551 |
|
| 2020 |
Sivagnanalingam U, Beatty PL, Finn OJ. Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention. Molecular Carcinogenesis. PMID 32333615 DOI: 10.1002/Mc.23206 |
0.631 |
|
| 2020 |
Hashash JG, Beatty PL, Critelli K, Hartman DJ, Regueiro M, Tamim H, Regueiro MD, Binion DG, Finn OJ. Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn's Disease. Journal of Clinical Gastroenterology. PMID 32195770 DOI: 10.1097/Mcg.0000000000001340 |
0.573 |
|
| 2019 |
Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Frontiers in Immunology. 10: 1401. PMID 31275327 DOI: 10.3389/Fimmu.2019.01401 |
0.671 |
|
| 2018 |
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Beatty PL, Kastenberg D, Hur C, Dzubinski L, Rodriguez L, Salazar A, McKolanis J, Seisler D, Foster NR, Polley M, Limburg PJ, et al. Abstract LB-305: Randomized, double-blind, placebo-controlled immunoprevention trial with MUC1 vaccine in patients with newly diagnosed advanced adenomas Immunology. DOI: 10.1158/1538-7445.Am2018-Lb-305 |
0.548 |
|
| 2018 |
Schoen RE, Boardman LA, Cruz-Correa MR, Bansal A, Kastenberg DM, Hur C, Dzubinski L, Rodriguez L, Salazar A, McKolanis J, Beatty P, Pai R, Seisler D, Foster NR, Polley M, et al. Mo1987 - Randomized, Double-Blind, Placebo-Controlled Immunoprevention Trial with MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas Gastroenterology. 154: S-873. DOI: 10.1016/S0016-5085(18)32950-0 |
0.548 |
|
| 2017 |
Cascio S, Faylo JL, Sciurba JC, Xue J, Ranganathan S, Lohmueller JJ, Beatty PL, Finn OJ. Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer. Oncotarget. 8: 105284-105298. PMID 29285251 DOI: 10.18632/Oncotarget.22168 |
0.572 |
|
| 2017 |
Hashash JG, Beatty P, Critelli K, Regueiro M, Hartman DJ, Regueiro MD, Binion DG, Goldby-Reffner K, Finn OJ. Overexpression and Hypoglycosylation of MUC1 is Associated with Endoscopic Recurrence of Post-Operative Crohn’s Disease Gastroenterology. 152: S210. DOI: 10.1016/S0016-5085(17)31006-5 |
0.541 |
|
| 2016 |
Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, Finn OJ. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunology, Immunotherapy : Cii. PMID 27106024 DOI: 10.1007/S00262-016-1838-1 |
0.647 |
|
| 2016 |
Finn OJ, Beatty PL. Cancer immunoprevention. Current Opinion in Immunology. 39: 52-8. PMID 26799207 DOI: 10.1016/j.coi.2016.01.002 |
0.59 |
|
| 2016 |
Hashash JG, Beatty P, Regueiro M, Hartman DJ, Binion DG, Landau M, Finn OJ. Abnormal MUC1 Expression in Post-operative Crohnʼs Disease Recurrence American Journal of Gastroenterology. 111: S306-S307. DOI: 10.14309/00000434-201610001-00673 |
0.546 |
|
| 2014 |
Iheagwara UK, Beatty PL, Van PT, Ross TM, Minden JS, Finn OJ. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunology Research. 2: 263-73. PMID 24778322 DOI: 10.1158/2326-6066.Cir-13-0125 |
0.669 |
|
| 2013 |
Beatty PL, Finn OJ. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Annals of the New York Academy of Sciences. 1284: 52-6. PMID 23651193 DOI: 10.1111/Nyas.12108 |
0.655 |
|
| 2012 |
Beatty P, Ranganathan S, Finn OJ. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology. 1: 263-270. PMID 22737601 DOI: 10.4161/Onci.18950 |
0.67 |
|
| 2011 |
Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunologic Research. 50: 261-8. PMID 21717081 DOI: 10.1007/S12026-011-8214-1 |
0.573 |
|
| 2011 |
Beatty PL, Cascio S, Lutz E. Tumor immunology: basic and clinical advances. Cancer Research. 71: 4338-43. PMID 21712409 DOI: 10.1158/0008-5472.Can-11-0717 |
0.4 |
|
| 2010 |
Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer Cancer Prevention Research. 3: 438-446. PMID 20332301 DOI: 10.1158/1940-6207.Capr-09-0194 |
0.701 |
|
| 2010 |
Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas. 39: 510-5. PMID 20084048 DOI: 10.1097/Mpa.0B013E3181Bd6501 |
0.576 |
|
| 2008 |
Beatty P, Kadayakkara D, Turner M, Janjic J, Ahrens E, Finn O. Overexpression of abnormal epithelial glycoprotein MUC1 is associated with pancreatitis and other extraintestinal complications in inflammatory bowel disease (IBD) The Faseb Journal. 22: 450-450. DOI: 10.1096/Fasebj.22.2_Supplement.450 |
0.569 |
|
| 2007 |
Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. Journal of Immunology (Baltimore, Md. : 1950). 179: 735-9. PMID 17617560 DOI: 10.4049/Jimmunol.179.2.735 |
0.617 |
|
| Show low-probability matches. |